Sergliflozin etabonate

Sergliflozin etabonate is a pharmaceutical drug that belongs to the class of SGLT2 inhibitors. It is an experimental drug that was developed for the treatment of Type 2 diabetes and obesity.

History[edit | edit source]

Sergliflozin etabonate was developed by Kissei Pharmaceutical Co., Ltd. and LG Life Sciences. The drug was in Phase II clinical trials for the treatment of type 2 diabetes and obesity, but development was discontinued in 2011.

Mechanism of Action[edit | edit source]

As an SGLT2 inhibitor, sergliflozin etabonate works by inhibiting the sodium-glucose transport proteins that are responsible for glucose reabsorption in the kidney. This results in an increase in glucose excretion through urine, thereby reducing blood glucose levels.

Clinical Trials[edit | edit source]

In Phase II clinical trials, sergliflozin etabonate showed promising results in reducing HbA1c levels and body weight in patients with type 2 diabetes and obesity. However, the development of the drug was discontinued due to concerns about its long-term safety and efficacy.

References[edit | edit source]

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

‎

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.